Welcome to our dedicated page for Viatris SEC filings (Ticker: VTRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viatris Inc. filings document the reporting record of a global healthcare company whose common stock trades on Nasdaq under VTRS. Form 8-K disclosures cover operating results, guidance and material events, including leadership transitions, restructuring actions from an enterprise-wide strategic review, bylaw amendments and shareholder-meeting matters.
Proxy statements describe board oversight, executive compensation, shareholder voting proposals, director nominations and governance practices. The filings also provide formal records for Viatris' capital return activity, strategic priorities, pipeline and product references, and the company's history as the combination of Mylan with Pfizer's Upjohn business.
SIMMONS DAVID S reported acquisition or exercise transactions in this Form 4 filing.
Viatris Inc director David S. Simmons received a grant of 2,362 deferred stock units (DSUs) on June 30, 2026 as compensation for quarterly non-employee director fees, in lieu of cash. The award was valued using the June 30, 2026 closing price of $15.88 per share of Viatris common stock.
Each DSU is fully vested and represents the right to receive one share of Viatris common stock. The DSUs will be settled in shares upon the earliest of Simmons’ termination of service as a non-employee director, his death or disability, or a change in control of Viatris.
Groothuis Leo Frans reported acquisition or exercise transactions in this Form 4 filing.
Viatris Inc. director Leo Frans Groothuis received a grant of 2,756 deferred stock units (DSUs) on June 30, 2026 as compensation in lieu of cash quarterly non-employee director fees. Each DSU is fully vested and represents one share of Viatris common stock, deliverable upon certain future events such as termination of service or a change in control.
Viatris Inc. has entered into an amended and restated term loan credit agreement providing a senior unsecured term loan facility of ¥40,000,000,000. The company plans to use the funds for general corporate purposes, including repaying its prior ¥40,000,000,000 unsecured term loan facility dated July 1, 2021.
The new Term Loan Credit Facility initially bears interest at the TIBO Rate plus 1.10% per year, with the margin adjustable based on Viatris’ long-term unsecured debt ratings. It includes customary covenants and a financial covenant requiring a leverage ratio no greater than 3.75 to 1.00 at each quarter-end after closing.
The facility is guaranteed by certain subsidiaries and matures three years from the closing date, with amounts voluntarily prepayable at any time without penalty other than customary breakage costs.
Viatris Inc officer Paul Campbell reported selling 50,076 shares of common stock in an open-market transaction at a weighted average price of $16.1711 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 24, 2026, and Campbell now holds 316,212 shares directly plus 318 shares indirectly through a 401(k) plan.
Viatris Inc. submitted a Rule 144 notice listing Common Stock eligible for sale under Rule 144. The excerpt lists specific compensatory vesting entries, including 361 shares dated 03/04/2023 and 49,715 shares dated 03/02/2024. The filing identifies NASDAQ as the market and includes securities data shown in the excerpt.
Viatris Inc. completed a public offering of €650,000,000 aggregate principal amount of 4.250% senior unsecured notes due June 17, 2033, guaranteed by Mylan Inc., Mylan II B.V. and Utah Acquisition Sub Inc. The notes were issued under an existing shelf registration.
The company intends to use the net proceeds mainly to repay amounts borrowed under its revolving credit facility that funded the repayment at maturity of $1.675 billion of 3.950% senior notes due 2026, with any remainder to replenish cash for general corporate purposes. The notes pay 4.250% interest annually starting June 17, 2027, include optional redemption before and after an April 17, 2033 par call date, and require a 101% repurchase offer upon certain change of control events.
Viatris Inc. entered into an underwriting agreement to issue and sell €650,000,000 principal amount of 4.250% Senior Notes due 2033. The notes will be offered under an effective shelf registration on Form S-3, using a prospectus dated May 8, 2025 and a prospectus supplement dated June 12, 2026.
The offering is expected to close on June 17, 2026, subject to customary closing conditions. BNP Paribas, Citigroup Global Markets Limited and Goldman Sachs & Co. LLC are acting as representatives of the underwriters. The agreement includes customary representations, warranties and termination provisions.
Viatris Inc. is offering €650,000,000 of 4.250% Senior Notes due June 17, 2033. Interest is payable annually on June 17 beginning June 17, 2027. The notes are senior unsecured and initially guaranteed by Mylan Inc., Mylan II B.V. and Utah Acquisition Sub Inc.
Net proceeds are estimated at approximately €644.0 million and are intended to fund repayment of borrowings used to redeem the $1.675 billion 2026 Senior Notes and to replenish cash for general corporate purposes. The offering will settle on or about June 17, 2026 and listing on Euronext Dublin has been applied for.
Viatris Inc. reported the results of its 2026 annual shareholder meeting, where three proposals were considered. Shareholders elected thirteen director nominees to serve until the 2027 annual meeting, with each nominee receiving a clear majority of votes cast in favor.
Shareholders also approved, on a non-binding advisory basis, the 2025 compensation of the company’s named executive officers, with 846,370,157 votes for, 26,920,688 against, and 2,266,069 abstentions, plus 122,461,640 broker non-votes. They further ratified the selection of Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026, with 969,259,214 votes for, 27,657,863 against, and 1,101,477 abstentions.